Early Academic Career (Tidig Akademisk Karriär)
Supports early-career researchers at Swedish universities conducting applied industry-linked research.
Tidig Akademisk Karriär (Early Academic Career) is KK-stiftelsen's program for recently postdoctoral researchers at Swedish newer universities, funding applied research conducted in genuine collaboration with private-sector partners. The program replaced the former Prospekt scheme from 2025. KK-stiftelsen funds research and competence development at 22 eligible institutions — all established after…
Funds early-career postdoctoral researchers at Swedish newer universities to conduct applied research projects in collaboration with at least two industry partners, across any technological discipline.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see the timeline
Sign up free to see where teams trip up
Guides for this application
All guides →Grants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
Where to applyGrants for Robotics Startups: SBIR, Defense, NSF, and Pilot Funding
A practical guide to grants for robotics startups, including SBIR/STTR, NSF, DoD, NASA, field validation, TRL, pilot evidence, budgets, and commercialization strategy.
BudgetGrant Financials and Co-Funding Evidence: Examples for Startup Applications
See examples of grant financials, match funding evidence, co-funding tables, accountant letters, investor commitments, and budget-to-work-plan checks.
DocumentsLetter of Support for Grant Applications: Template and Examples
Learn how to write and request a letter of support for a grant, with template structure, examples, reviewer logic, and common mistakes.
More from KK-stiftelsen
All grants from this funder →Avans (Mini and Maxi)
🇸🇪KK-stiftelsen · Sweden
Offers development of advanced masters programmes at Swedish universities to strengthen future knowledge-based workforce pathways.
Forskningsprofiler/26 Call
🇸🇪KK-stiftelsen · Sweden
Supports Swedish universities in building lasting applied research environments with strong industry collaboration.
Forskningsprojekt
🇸🇪KK-stiftelsen · Sweden
Supports collaborative applied research projects at Swedish universities through shorter-to-medium term funding opportunities.
Industrial Graduate Schools (Företagsforskarskolor)
🇸🇪KK-stiftelsen · Sweden
Funds industrial doctoral school models in Sweden that connect doctoral training with practical company collaboration.
Synergi/26 Call
🇸🇪KK-stiftelsen · Sweden
Funds large integrated Swedish research programs linking multiple projects around one strategic scientific objective.
Similar grants
Browse the directory →
Innowwide — Next
🇪🇺EUREKA · Global / Multinational
Offers market-feasibility support for small companies exploring non-European markets through Europe-wide innovation networks.
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research
NIH · United States
Funds proof-of-concept work on a genuinely new tool, assay, platform or instrument for characterising cancer cells or handling biospecimens.
Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research
NIH · United States
Funds early proof-of-concept work testing whether a new cancer research tool, assay, platform or instrument is technically feasible at all.
EIC Accelerator Challenges
🇪🇺EIC · European Union
Funds strategic deep-tech challenge projects in materials, energy, biotechnology, and climate innovation.
Mission Soil and Cancer: Living Labs for Carcinogenic Contamination
🇪🇺European Commission · European Union
Funds two €12M projects using living labs to remediate carcinogenic soils and trace cancer risks through people, food, water and air.
Cancer Mission: First-in-Human Trials for Rare Cancers
🇪🇺European Commission · European Union
Funds €7–9M projects taking biomarker-guided rare-cancer treatments into first-in-human, multicentre phase 1 trials.